News | May 16, 2024
Cipla invests additional Rs. 26 crore in Achira
Achira is engaged in development and commercialization of PoC medical test kits in India
Achira is engaged in development and commercialization of PoC medical test kits in India
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Subscribe To Our Newsletter & Stay Updated
